Harald Hofer

8.9k citations

73 papers · 4.0k indexed · 1 hit paper · h-index 32

Impact in

Hepatology top 0.2%
- Hepatitis C virus research
- Liver Diseases and Immunity
- Liver Disease and Transplantation
Epidemiology top 0.5%
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies

Papers in

Hepatology 53
- Hepatitis C virus research 41
- Liver Disease and Transplantation 14
- Liver Diseases and Immunity 7
Epidemiology 49
- Liver Disease Diagnosis and Treatment 43
- Hepatitis B Virus Studies 19

Co-authors: Péter Ferenci Petra Steindl‐Munda S. Beinhardt Michael Trauner Hans‐Peter Dienes Minoru Shibata Kirsten Muri Boberg Mikio Zeniya
Journals: Journal of Hepatology (12 papers)Gastroenterology (8 papers)Liver International (7 papers)Digestive Diseases (5 papers)Hepatology (5 papers)
Partner nations: Austria Germany United States

In The Last Decade

Harald Hofer

71 papers receiving 3.9k citations

Hit Papers

align trajectories log scale

Simplified criteria for the diagnosis of autoimmune hepatitis† 2008 · 1.2k citations

Peers

Countries citing papers authored by Harald Hofer

Since Specialization

Citations

This map shows the geographic impact of Harald Hofer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harald Hofer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harald Hofer more than expected).

Fields of papers citing papers by Harald Hofer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harald Hofer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harald Hofer. The network helps show where Harald Hofer may publish in the future.

Co-authors

The 25 scholars most cited alongside Harald Hofer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Harald Hofer Line = papers co-authored together Harald Hofer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Ausbildung und Fortbildung in der Gastroenterologie und Hepatologie Heinz F. Hammer, Michael Gschwantler, Harald Hofer, Peter Fickert	2023	2
2	Treatment of colonic varices and gastrointestinal bleeding by recanalization and stenting of splenic-vein-thrombosis: A case report and literature review World Journal of Gastroenterology ·Lisa-Michaela Füssel, René Müller‐Wille, Patrick Dinkhauser, Walter Schauer, Harald Hofer	2023	3
3	Consensus Statement der Österreichischen Gesellschaften für Rheumatologie und Rehabilitation, Pneumologie, Infektiologie, Dermatologie und Gastroenterologie zum Umgang mit latenter Tuberkulose bei Therapien mit biologischen oder „targeted synthetic“ DMARDs („disease modifying antirheumatic drugs“) Zeitschrift für Rheumatologie ·Eva Rath, Michael Bonelli, Christina Duftner, Johann Gruber, Péter Mandl, Florentine Moazedi‐Fürst, Herwig Pieringer, Rudolf Puchner, Holger Flick, Helmut J.F. Salzer, Günter Weiß, Stefan Winkler, Hans Skvara, Alexander R. Moschen, Harald Hofer, Julia Feurstein, Judith Sautner	2022	3
4	Real-world clinical practice outcomes in hepatitis C-infected patients with psychiatric and substance use disorders treated with glecaprevir/pibrentasvir for 8 or 12 weeks: a pooled analysis across nine countries Journal of Hepatology ·Pietro Lampertico, Robert Flisiak, Nuno Marques, Olivier Clerc, Ioannis Goulis, Mark Bondin, Ariel Porcalla, Zhenzhen Zhang, Yves Horsmans, Harald Hofer, Ella Veitsman, Georges‐Philippe Pageaux	2020	2
5	Ultra‐high‐field magnetic resonance spectroscopy in non‐alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non‐alcoholic steatohepatitis and advanced fibrosis Liver International ·Stefan Traussnigg, Christian Kienbacher, Martin Gajdošík, Ladislav Valkovič, Emina Halilbasic, Judith Stift, Christian Rechling, Harald Hofer, Petra Steindl‐Munda, Péter Ferenci, Fritz Wrba, Siegfried Trattnig, Martin Krššák, Michael Trauner	2017	36
6	The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease BMC Infectious Diseases ·Jim Young, Nina Weis, Harald Hofer, William L. Irving, Ola Weiland, Emiliano Giostra, J.M. Pascasio, Lluı́s Castells, M. Prieto, Roelien Postema, Cinira Lefèvre, David Evans, Heiner C. Bucher, José Luís Calleja	2017	13
7	von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy Digestive and Liver Disease ·Karoline Rutter, A. Etschmaier, Monika Ferlitsch, A Maieron, S Hametner, Thomas Horvatits, Rafael Paternostro, Petra Salzl, Thomas Reiberger, Markus Peck‐Radosavljevic, Peter Quehenberger, Harald Hofer, Michael Trauner, Péter Ferenci, Arnulf Ferlitsch	2016	1
8	Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension Journal of Hepatology ·Mattias Mandorfer, K Kozbial, Philipp Schwabl, C Freissmuth, Rémy Schwarzer, R Stern, David Chromy, Albert Friedrich Stättermayer, Thomas Reiberger, S. Beinhardt, Wolfgang Sieghart, Michael Trauner, Harald Hofer, Arnulf Ferlitsch, Péter Ferenci, Markus Peck‐Radosavljevic	2016	213
9	Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE: Table 1. Clinical Infectious Diseases ·Marı́a Buti, Stuart C. Gordon, Eli Zuckerman, Eric Lawitz, José Luís Calleja, Harald Hofer, Christopher L. Gilbert, John Palcza, Anita Y. M. Howe, Mark J. DiNubile, Michael Robertson, Janice Wahl, Eliav Barr, Xavier Forns	2015	77
10	Hepatic steatosis in Wilson disease – Role of copper and PNPLA3 mutations Journal of Hepatology ·Albert Friedrich Stättermayer, Stefan Traussnigg, Hans‐Peter Dienes, Elmar Aigner, Rudolf Stauber, K. Lackner, Harald Hofer, Judith Stift, Friedrich Wrba, Andreas Stadlmayr, Christian Datz, Michael Straßer, A Maieron, Michael Trauner, Péter Ferenci	2015	73
11	Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent Journal of Hepatology ·Xavier Forns, Stuart C. Gordon, Eli Zuckerman, Eric Lawitz, José Luís Calleja, Harald Hofer, Christopher L. Gilbert, John Palcza, A Howe, Mark J. DiNubile, Michael Robertson, Janice Wahl, Eliav Barr, Marı́a Buti	2015	109
12	Real-Time PCR Assays for the Quantification of HCV RNA: Concordance, Discrepancies and Implications for Response Guided Therapy PLoS ONE ·Robert Straßl, Karoline Rutter, Albert Friedrich Stättermayer, S. Beinhardt, Michael Kammer, Harald Hofer, Péter Ferenci, Theresia Popow‐Kraupp	2015	14
13	Therapeutic Role of Bile Acids and Nuclear Receptor Agonists in Fibrosing Cholangiopathies Digestive Diseases ·Michael Trauner, Emina Halilbasic, Lili Kazemi-Shirazi, Christian Kienbacher, Katharina Staufer, Stefan Traussnigg, Harald Hofer	2014	10
14	Peginterferon Alfa-2a/Ribavirin for 48 or 72 Weeks in Hepatitis C Genotypes 1 and 4 Patients With Slow Virologic Response Gastroenterology ·Peter Ferenci, Hermann Laferl, Thomas–Matthias Scherzer, A Maieron, Harald Hofer, Rudolf Stauber, Michael Gschwantler, H. Brünner, Christoph Wenisch, Martin Bischof, Michael Straßer, Christian Datz, Wolfgang Vogel, Karin Löschenberger, Petra Steindl‐Munda	2009	86
15	Simplified criteria for the diagnosis of autoimmune hepatitis† Hepatology ·Elke Hennes, Mikio Zeniya, Albert J. Czaja, Albert Parés, George N. Dalekos, Edward L. Krawitt, Paulo Lisboa Bittencourt, Gilda Porta, Kirsten Muri Boberg, Harald Hofer, Francesco B. Bianchi, Minoru Shibata, Christoph Schramm, Bárbara Torres, Peter R. Galle, Ian G. McFarlane, Hans‐Peter Dienes, Ansgar W. Lohse Hit paper breakdown →	2008	1202
16	Silibinin Is a Potent Antiviral Agent in Patients With Chronic Hepatitis C Not Responding to Pegylated Interferon/Ribavirin Therapy Gastroenterology ·Péter Ferenci, Thomas–Matthias Scherzer, Heidrun Kerschner, Karoline Rutter, S. Beinhardt, Harald Hofer, Maximilian Schöniger–Hekele, Heidemarie Holzmann, Petra Steindl‐Munda	2008	178
17	A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3 Hepatology ·Péter Ferenci, H. Brünner, Hermann Laferl, Thomas–Matthias Scherzer, A Maieron, Michael Straßer, Gabriele Fischer, Harald Hofer, Martin Bischof, Rudolf Stauber, Michael Gschwantler, Petra Steindl‐Munda, Katharina Staufer, Karin Löschenberger	2008	49
18	Impact of high‐dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy Liver International ·Petra Steindl‐Munda, Peter Ferenci, H. Brünner, Karin Nachbaur, Christian Datz, Michael Gschwantler, Harald Hofer, Rudolf Stauber, Franz Hackl, Wolfgang Jessner, Martha Rosenbeiger, Alfred Gangl, Wolfgang Vogel, (unknown)	2003	11
19	Rapid suppression of hematopoiesis by standard or pegylated interferon-α Gastroenterology ·Markus Peck‐Radosavljevic, Martina Wichlas, Monika Homoncik–Kraml, Anna Kreil, Harald Hofer, Wolfgang Jessner, Alfred Gangl, Peter Ferenci	2002	109
20	25-Hydroxyvitamin D3-1α-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis Steroids ·Heide S. Cross, Petra Bareis, Harald Hofer, Martin Bischof, Erika Bajna, Stefan Kriwanek, Elisabeth Bonner, Meinrad Peterlik	2001	164

About Harald Hofer

Harald Hofer is a scholar working on Hepatology, Epidemiology, Rheumatology, Hematology and Pharmacology, having authored 73 papers that have together received 4.0k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (43 papers), Hepatitis C virus research (41 papers), Hepatitis B Virus Studies (19 papers), Liver Disease and Transplantation (14 papers), Liver Diseases and Immunity (7 papers), Systemic Lupus Erythematosus Research (6 papers), Trace Elements in Health (5 papers) and Drug Transport and Resistance Mechanisms (5 papers). The work is most often cited by research in Hepatology (3.0k citations), Epidemiology (2.7k citations), Pharmacology (280 citations), Rheumatology (463 citations) and Nutrition and Dietetics (288 citations). Harald Hofer has collaborated with scholars based in Austria, Germany and United States. Frequent co-authors include Péter Ferenci, Petra Steindl‐Munda, S. Beinhardt, Michael Trauner, Hans‐Peter Dienes, Minoru Shibata, Kirsten Muri Boberg, Mikio Zeniya, George N. Dalekos and Albert J. Czaja. Their work appears in journals such as Journal of Hepatology, Gastroenterology, Liver International, Digestive Diseases and Hepatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact